Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30239158 | 0.88 | MAPK1 (0.47) | CKS1BSKP1SKP2BTKKMT2A | |
| SCHEMBL30239072 | 0.82 | IDO1 (0.44) | KMT2AIDO1L3MBTL1MALT1DRD2 | |
| SCHEMBL21564331 | 0.82 | ALDH1A1 (0.40) | KMT2AALDH1A1IDO1MALT1DRD2 | |
| SCHEMBL15472754 | 0.81 | BTK (0.54) | CKS1BSKP1SKP2BTKKMT2A | |
| SCHEMBL18765005 | 0.79 | DGAT1 (0.40) | KMT2AALDH1A1IDO1MALT1DRD2 | |
| SCHEMBL17274051 | 0.78 | PDE10A (0.49) | CKS1BSKP1SKP2KMT2AIDO1 | |
| SCHEMBL24931213 | 0.77 | JAK2 (0.42) | KMT2AALDH1A1L3MBTL1DRD2 | |
| SCHEMBL17273760 | 0.77 | HDAC3 (0.51) | CKS1BSKP1SKP2KMT2ADRD2 | |
| SCHEMBL14737075 | 0.77 | PDE10A (0.50) | CKS1BSKP1SKP2IDO1MALT1 | |
| SCHEMBL31518543 | 0.76 | MEN1 (0.38) | KMT2AALDH1A1MALT1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118401507-A | Inhibitors targeting ubiquitin-specific protease 7 (USP 7) | 丹娜法伯癌症研究院 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023003973-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | CKS1B 637/4885SKP1 2375/4885SKP2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.